截至11月26日收盘，医药电商概念上涨1.38%，位居概念板块涨幅第5，板块内，96股上涨，粤万年 青、华人健康等20%涨停，中恒集团、人民同泰、瑞康医药等涨停，悦康药业、漱玉平民、莱美药业等 涨幅居前，分别上涨12.00%、9.35%、7.78%。跌幅居前的有华瑞股份、昌红科技、健麾信息等，分别 下跌3.08%、2.68%、2.26%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 赛马概念 | 1.95 | 中船系 | -5.09 | | 同花顺果指数 | 1.95 | 兵装重组概念 | -3.05 | | 免税店 | 1.72 | 国产航母 | -2.50 | | 广东自贸区 | 1.50 | 军民融合 | -1.90 | | 医药电商 | 1.38 | 核污染防治 | -1.85 | | 共封装光学(CPO) | 1.27 | 军工信息化 | -1.82 | | 同花顺出海50 | 1.24 | 电子身份证 | -1.82 | | 培育钻石 | 1.21 | 成飞概念 | -1.80 | | 拼多多 ...

Market Performance - As of November 14, the pharmaceutical e-commerce sector rose by 1.24%, ranking 9th among concept sectors, with 93 stocks increasing in value [1] - Notable gainers included Shuyuan Pharmaceutical and Kangzhi Pharmaceutical, both reaching a 20% limit up, while Jiaying Pharmaceutical and People's Tongtai also hit the limit up [1] - The top gainers in the sector included Jinshiyao, Minsheng Health, and Jiashitang, which rose by 8.10%, 7.62%, and 5.97% respectively [1] Capital Inflow - The pharmaceutical e-commerce sector saw a net inflow of 1.058 billion yuan, with 70 stocks receiving net inflows, and 5 stocks exceeding 100 million yuan in net inflow [2] - The leading stock in terms of net inflow was Zhongsheng Pharmaceutical, with a net inflow of 732 million yuan, followed by Te Yi Pharmaceutical and Kangzhi Pharmaceutical with net inflows of 299 million yuan and 258 million yuan respectively [2] Stock Performance - The stocks with the highest net inflow ratios included ST Zhongzhu, Shuyuan Pharmaceutical, and Zhongsheng Pharmaceutical, with net inflow ratios of 42.18%, 37.31%, and 36.05% respectively [3] - Notable stock performances included Zhongsheng Pharmaceutical and Te Yi Pharmaceutical both achieving a 9.98% increase, while Kangzhi Pharmaceutical reached a 20% increase [3][4] Additional Insights - The pharmaceutical e-commerce sector's performance was supported by significant capital inflows, indicating strong investor interest [2][3] - The overall market sentiment appears positive for the pharmaceutical e-commerce sector, as evidenced by the number of stocks hitting the upper limit and the substantial net inflows [1][2]

Market Performance - As of August 1, the pharmaceutical e-commerce sector rose by 1.51%, ranking 9th among concept sectors, with 114 stocks increasing in value [1] - Notable gainers included Weikang Pharmaceutical with a 20% limit-up, and New Tian Pharmaceutical, Huason Pharmaceutical, and Qizheng Tibetan Medicine also hitting the limit-up [1] - The top performers in the sector were Shenzhou Pharmaceutical, Dajia Weikang, and Zhongsheng Pharmaceutical, with increases of 23.15%, 8.87%, and 7.49% respectively [1] Capital Flow - The pharmaceutical e-commerce sector saw a net inflow of 899 million yuan from main funds, with 84 stocks receiving net inflows [2] - Leading the net inflow was Zhongsheng Pharmaceutical with 533 million yuan, followed by Huason Pharmaceutical, Taiji Group, and New Tian Pharmaceutical with net inflows of 111 million yuan, 98 million yuan, and 82 million yuan respectively [2] Stock Performance - New Tian Pharmaceutical, Weikang Pharmaceutical, and Kefu Medical had the highest net inflow ratios at 43.47%, 16.51%, and 15.73% respectively [3] - The top stocks in the pharmaceutical e-commerce sector based on net inflow included Zhongsheng Pharmaceutical, Huason Pharmaceutical, and Taiji Group, with respective daily increases of 7.49%, 10.03%, and 4.09% [3] Decliners - The stocks with the largest declines included Erkang Pharmaceutical, Kangzhi Pharmaceutical, and Laimei Pharmaceutical, which fell by 9.59%, 7.15%, and 5.81% respectively [1][10] - The overall market showed mixed performance with some sectors experiencing significant losses while others gained traction [10]

Group 1 - The pharmaceutical e-commerce sector saw a rise of 2.00%, ranking 8th among concept sectors, with 124 stocks increasing in value [1] - Notable gainers included Rundu Co., Aosaikang, and Wanbangde, which reached their daily limit up, while Furuishi and Laimei Pharmaceuticals also performed well with increases of 9.55%, 8.48%, and 5.54% respectively [1] - The sector experienced a net inflow of 750 million yuan from main funds, with 83 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Rundu Co. led the net inflow with 145 million yuan, followed by Yipin Hong, Furuishi, and Zhongsheng Pharmaceuticals with net inflows of 98.68 million yuan, 83.98 million yuan, and 70.42 million yuan respectively [2] - In terms of net inflow ratio, Rundu Co. had a leading rate of 42.20%, followed by Zhejiang Zhenyuan and ST Huluwawa at 29.25% and 16.55% respectively [3] Group 3 - The pharmaceutical e-commerce concept had a total of 124 stocks rising, with significant contributions from stocks like Rundu Co. and Aosaikang, which both showed strong performance [1][2] - The overall market sentiment in the pharmaceutical e-commerce sector appears positive, as indicated by the substantial net inflows and the number of stocks experiencing gains [2][3]